epitheli
ovarian
carcinoma
eoca
usual
asymptomat
earli
stage
develop
patient
diseas
often
widespread
time
diagnosi
partli
due
absenc
sensit
reliabl
serolog
marker
current
accept
serum
marker
diagnosi
eoca
limit
sensit
detect
approxim
patient
stage
diseas
women
advanc
cancer
moreov
lack
specif
also
elev
nonovarian
malign
benign
gynecolog
disord
normal
case
addit
sever
gynecolog
disord
ovarian
cyst
uterin
leiomyoma
pelvi
inflammatori
diseas
endometriosi
produc
higher
level
advanc
proteom
analysi
gener
much
interest
prospect
identifi
complementari
biomark
diagnos
variou
cancer
gelbas
proteom
studi
perform
unfraction
whole
serum
sampl
patient
differ
type
cancer
demonstr
differ
alter
express
select
serum
high
abund
acutephas
protein
app
sera
patient
eoca
germlin
ovarian
carcinoma
breast
cancer
nasopharyng
carcinoma
endometri
adenocarcinoma
squamou
cell
cervic
carcinoma
adenocerv
carcinoma
osteosarcoma
case
eoca
enhanc
express
act
clusterin
clu
aat
fragment
aatf
haptoglobin
hap
well
cleav
fragment
hapc
leucin
rich
glycoprotein
lrg
detect
serum
sampl
cancer
patient
compar
control
individu
present
studi
express
overexpress
high
abund
acutephas
protein
app
sera
eoca
patient
analys
accord
stage
cancer
serum
sampl
obtain
newli
diagnos
eoca
patient
age
year
differ
stage
cancer
stage
n
stage
ii
n
stage
iii
n
stage
iv
n
univers
malaya
medic
centr
ummc
prior
treatment
stage
eoca
perform
accord
intern
feder
gynecolog
obstetr
figo
clinic
stage
system
control
sera
obtain
agematch
voluntari
women
without
cancer
sampl
obtain
consent
approv
grant
ethic
committe
institut
review
board
ummc
accord
declar
helsinki
ich
gcp
guidelin
twodimension
gel
electrophoresi
perform
previous
describ
unfraction
whole
human
serum
sampl
subject
isoelectr
focus
rehydr
precast
immobil
dri
strip
ph
ge
healthcar
bioscienc
uppsala
sweden
focus
sampl
strip
subject
electrophoresi
use
gradient
polyacrylamid
gel
presenc
sodium
dodecyl
sulfat
sdspage
sampl
analyz
duplic
gel
develop
silver
stain
describ
heukeshoven
dernick
mass
spectrometr
analysi
gel
stain
coomassi
blue
accord
modifi
method
shevchenko
et
al
confirm
ident
app
spot
cluster
mass
spectrometri
use
ettan
malditof
pro
previous
describ
peaklist
data
obtain
pmf
gener
use
ettan
maldi
softwar
releas
version
seri
explor
softwar
releas
version
respect
data
export
mascot
search
engin
matrix
scienc
ltd
london
uk
releas
version
follow
paramet
use
search
enzym
trypsin
ii
one
miss
cleavag
allow
iii
taxonomi
limit
homo
sapien
iv
mass
valu
monoisotop
v
peptid
mass
toler
da
vi
peptid
charg
state
imag
gel
captur
use
labscan
imag
scanner
version
protein
profil
evalu
use
platinum
softwar
version
elimin
possibl
variat
due
differenti
protein
stain
load
express
protein
evalu
percentag
volum
contribut
vol
refer
volum
percentag
protein
taken
total
spot
volum
protein
level
protein
gel
present
mean
vol
sd
respect
number
sampl
cohort
patient
control
analys
normal
test
z
use
analyz
signific
differ
control
subject
patient
examin
correl
variabl
pvalu
less
p
consid
statist
signific
subject
unfraction
serum
sampl
eoca
patient
neg
control
femal
subject
silver
stain
gener
typic
highli
resolv
profil
high
abund
protein
fig
demonstr
repres
serum
protein
profil
neg
control
women
panel
eoca
patient
variou
stage
diseas
panel
confirm
ident
variou
serum
high
abund
app
describ
previou
report
act
aat
lrg
clu
hap
spot
cluster
clearli
resolv
profil
howev
hapc
aatf
appear
detect
sera
eoca
patient
control
individu
clu
detect
sera
patient
stage
ii
panel
b
c
respect
stage
iii
iv
neg
control
women
cluster
high
abund
serum
protein
spot
control
women
cohort
patient
diagnos
differ
stage
eoca
analyz
densitometri
softwar
correl
stage
associ
express
app
demonstr
sera
patient
studi
invers
correl
initi
three
stage
cancer
appar
detect
express
clu
lrg
fig
panel
b
respect
howev
express
act
hap
aat
appear
increas
first
three
stage
eoca
fig
panel
c
e
respect
patient
diagnos
stage
iv
cancer
express
serum
app
conform
alter
progress
chang
express
hapc
aatf
demonstr
correl
stage
eoca
fig
panel
f
g
respect
rel
express
fold
chang
statist
signific
serum
high
abund
protein
eoca
patient
accord
stage
cancer
summar
tabl
result
experi
highlight
potenti
prognost
signific
sever
aberrantli
express
app
henc
need
conduct
studi
monitor
express
serum
protein
progress
eoca
present
studi
demonstr
correl
express
act
clu
hap
aat
lrg
patient
eoca
accord
three
initi
stage
cancer
use
gelbas
proteom
approach
howev
stagecorrel
express
observ
hapc
aatf
although
protein
fragment
gener
detect
protein
profil
normal
control
women
unlik
initi
three
stage
eoca
express
act
clu
hap
aat
lrg
sera
eoca
patient
stage
iv
conform
alter
progress
chang
observ
unexpect
app
respons
gener
expect
succumb
malign
final
stage
cancer
thu
affect
synthesi
liver
depend
sever
malign
liver
damag
late
stage
patient
level
app
may
may
correl
pattern
alter
progress
chang
correl
express
high
abund
serum
app
detect
present
studi
may
reflect
acutephas
respons
bodi
variou
initi
stage
eoca
upregul
express
clu
earli
stage
eoca
may
function
suppress
biolog
aggress
behavior
cancer
cell
exert
protect
function
surviv
cell
clu
report
confer
protect
variou
cytotox
agent
uv
radiat
heat
shock
oxid
stress
chemotherapeut
drug
case
non
small
cell
lung
breast
cancer
express
clu
demonstr
significantli
associ
relapsefre
metastasisfre
surviv
patient
taken
togeth
data
present
studi
suggest
prognost
signific
clu
cancer
concern
like
clu
present
studi
demonstr
enhanc
express
lrg
appear
invers
correl
progress
eoca
lrg
whose
function
unknown
consist
elev
sera
patient
bacteri
infect
often
increas
viral
infect
patient
sever
acutephas
respiratori
syndrom
also
note
enhanc
level
serum
lrg
case
cancer
increas
serum
lrg
observ
patient
liver
lung
pancreat
cancer
togeth
hap
also
one
high
abund
cancer
select
protein
identifi
studi
compar
trypsindigest
peptid
glycoprotein
isol
sera
healthi
individu
lung
adenocarcinoma
patient
asid
potenti
biomark
diagnosi
data
present
studi
suggest
prognost
valu
lrg
particularli
eoca
act
wellestablish
app
whose
function
primarili
associ
inflamm
level
previous
report
elev
sera
patient
eoca
breast
cancer
pancreat
cancer
sinc
serin
proteinas
inhibitor
known
form
complex
human
kallikrein
also
known
prostatespecif
antigen
shown
produc
number
tumor
includ
ovarian
tumor
like
excess
act
detect
sera
eoca
patient
part
complex
protein
howev
could
verifi
sinc
gelbas
approach
adopt
studi
involv
analysi
protein
denatur
form
express
hap
appear
peak
stage
iii
eoca
recent
report
zhao
et
al
also
demonstr
circul
hap
significantli
correl
stage
tumor
surviv
eoca
patient
accumul
data
impli
express
hap
affect
tumor
burden
signific
upregul
express
hapc
sera
eoca
patient
stage
observ
present
studi
suggest
cancer
associ
hap
rather
unstabl
prone
proteolysi
howev
gener
hapc
appear
correl
variou
stage
eoca
previous
report
studi
perform
lung
breast
cervic
cancer
patient
indic
correl
chang
level
serum
plasma
aat
especi
late
metastat
stage
diseas
compat
data
present
studi
signific
enhanc
express
aat
patient
eoca
stage
also
provid
explan
detect
cleav
fragment
spot
aatf
exclus
sampl
patient
lower
molecular
weight
aatf
like
gener
proteolyt
digest
abund
aat
within
cancer
microenviron
like
hapc
howev
cleavag
serum
protein
appear
correl
stage
eoca
differ
alter
stage
correl
express
clu
lrg
act
hap
aat
sera
patient
eoca
demonstr
present
studi
result
highlight
potenti
prognost
signific
high
abund
serum
app
patient
eoca
author
declar
compet
interest
yc
carri
experi
analyz
data
bkl
provid
serum
sampl
studi
share
clinic
expertis
epitheli
ovarian
carcinoma
ohh
conceptu
studi
design
author
manuscript
author
read
approv
final
manuscript
